摘要
目的:比较奥氮平与阿立哌唑治疗精神分裂症的疗效及安全性。方法:将60例精神分裂症患者随机分成两组,每组30例,分别给予奥氮平和阿立哌唑,疗程8周,采用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、治疗中出现的副反应量表(TESS)评定疗效和不良反应。结果:两组PANSS总分及CGI-SI评分均较治疗前显著下降(P<0.01),奥氮平组显效率77%,阿立哌唑组显效率73%,两组疗效相当(P>0.05)。奥氮平组嗜睡、体重增加的不良反应均明显高于阿立哌唑组(P<0.01),阿立哌唑组锥体外系反应、失眠、兴奋或激越明显高于奥氮平组(P<0.01)。结论:奥氮平与阿立哌唑治疗精神分裂症的疗效相当,奥氮平的安全性较高。
Objective：To compare the efficacy and safety of Olanzapine and Aripiprasole in the treatment of schizophrenia. Methods：60 patients with schizophrenia were randomly divided into two groups, each group of 30 cases, were given Olanzapine and Aripiprazole, treatment eight weeks, the curative effects and adverse reactions were assessed with PANSS, CGE SI and TESS. Resaltlts：Two groups of PANSS total cent and CGE - SI scores were relatively before treatment significantly （P 〈 O. 01 ）, Olanzapine group signifieat efficiency was 77% in Olanzapine group, and signifieat efficiency was 73% in Aripiprazole group. There was no significant difference between the two groups in the clinical efficacy（ P 〉 0. 05 ）. Lethargy and weight gain in Olanzapine group were significantly higher than those in Aripiprazole group（ P 〈 0.01 ）, extrapyramidal reactlons,insomnia, excited or vehement in Aripi- prazolc group were significantly higher tbean those in Olanzapine group（ P 〈 0.01 ）. Conclusion：There was no significant difference between Olanzapine and Aripiprazole in the clinical efficacy, Olanzapine security is higher.
出处
《中国民康医学》
2011年第18期2231-2232,共2页
Medical Journal of Chinese People’s Health
